Table 1.
Characteristics of patients in the training and validation cohorts.
| Characteristic | Training cohort n = 62 | Validation cohort n = 31 | p-value a |
|---|---|---|---|
| Patients, No. (%) | |||
| Age, mean (SD), year | 49.4 (11.2) | 52.9 (8.6) | .21 |
| Platinum sensitivity, No. (%) | .93 | ||
| Resistant | 12 (20) | 7 (23) | |
| Sensitive | 50 (80) | 24 (77) | |
| HIPEC, No. (%) | >.99 | ||
| ≥1 cycle | 24 (39) | 12 (39) | |
| Non | 38 (61) | 19 (61) | |
| FIGO stage b , No. (%) | .73 | ||
| I | 13 (21) | 8 (26) | |
| II | 4 (6) | 3 (10) | |
| III | 37 (60) | 18 (58) | |
| IV | 8 (13) | 2 (6) | |
| Histologic classification, No. (%) | .32 | ||
| Serous carcinoma | 39 (63) | 20 (65) | |
| Endometrioid carcinoma | 9 (15) | 1 (3) | |
| Clear cell carcinoma | 5 (8) | 6 (19) | |
| Mucinous carcinoma | 2 (3) | 1 (3) | |
| Special types | 7 (11) | 3 (10) | |
| Type of surgery, No. (%) | >.99 | ||
| PDS | 54 (87) | 27 (87) | |
| IDS | 8 (13) | 4 (13) | |
| Follow-up time, months (median [IQR]) | 21.0 [13.7, 33.2] | 23.2 [15.2, 43.3] | .44 |
FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation; HIPEC, hyperthermic intraperitoneal chemotherapy; PDS, primary debulking surgery; IDS, interval debulking surgery; IQR, interquartile range.
a
p-values represent the difference of each clinicopathologic variable between the training and validation cohorts.
b
2018 FIGO staging.